Immutep receives FDA orphan drug designation for eftilagimod alfa in soft tissue sarcoma
Immutep (NASDAQ:IMMP), a clinical-stage biotechnology company developing LAG-3 immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead product candidate, eftilagimod alfa (efti), for the treatment of soft tissue sarcoma (STS).










